201 related articles for article (PubMed ID: 38057328)
1. Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.
Vogt M; Dienstbier N; Schliehe-Diecks J; Scharov K; Tu JW; Gebing P; Hogenkamp J; Bilen BS; Furlan S; Picard D; Remke M; Yasin L; Bickel D; Kalia M; Iacoangeli A; Lenz T; Stühler K; Pandyra AA; Hauer J; Fischer U; Wagener R; Borkhardt A; Bhatia S
Cell Death Dis; 2023 Dec; 14(12):799. PubMed ID: 38057328
[TBL] [Abstract][Full Text] [Related]
2. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
3. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.
Bhatia S; Diedrich D; Frieg B; Ahlert H; Stein S; Bopp B; Lang F; Zang T; Kröger T; Ernst T; Kögler G; Krieg A; Lüdeke S; Kunkel H; Rodrigues Moita AJ; Kassack MU; Marquardt V; Opitz FV; Oldenburg M; Remke M; Babor F; Grez M; Hochhaus A; Borkhardt A; Groth G; Nagel-Steger L; Jose J; Kurz T; Gohlke H; Hansen FK; Hauer J
Blood; 2018 Jul; 132(3):307-320. PubMed ID: 29724897
[TBL] [Abstract][Full Text] [Related]
4. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
5. Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and HSP90 inhibitor resistances.
Arolla RG; Malladi S; Bhaduri U; Gayatri MB; Pattamshetty P; Mohan V; Katika MR; Madhava Reddy AB; Satyanarayana Rao MR; Vudem DR; Kancha RK
Biochem Biophys Res Commun; 2021 Jan; 534():461-467. PubMed ID: 33246559
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
7. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.
Millson SH; Truman AW; Rácz A; Hu B; Panaretou B; Nuttall J; Mollapour M; Söti C; Piper PW
FEBS J; 2007 Sep; 274(17):4453-63. PubMed ID: 17681020
[TBL] [Abstract][Full Text] [Related]
8. A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta.
Millson SH; Prodromou C; Piper PW
Biochem Pharmacol; 2010 Jun; 79(11):1581-8. PubMed ID: 20138026
[TBL] [Abstract][Full Text] [Related]
9. Proliferation, migration, and resistance to oxidative and thermal stresses of HT1080 cells with knocked out genes encoding Hsp90α and Hsp90β.
Petrenko V; Vrublevskaya V; Bystrova M; Masulis I; Kopylova E; Skarga Y; Zhmurina M; Morenkov O
Biochem Biophys Res Commun; 2023 Sep; 674():62-68. PubMed ID: 37406487
[TBL] [Abstract][Full Text] [Related]
10. The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep.
Chang C; Tang X; Woodley DT; Chen M; Li W
Cells; 2023 Jan; 12(2):. PubMed ID: 36672211
[TBL] [Abstract][Full Text] [Related]
11. CAMKIIγ, HSP70 and HSP90 transcripts are differentially expressed in chronic myeloid leukemia cells from patients with resistant mutated disease.
Gonzalez M; De Brasi C; Ferri C; Bengió R; Bianchini M; Larripa I
Leuk Lymphoma; 2014 Sep; 55(9):2101-8. PubMed ID: 24206096
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors.
Peng C; Li D; Li S
Cell Cycle; 2007 Sep; 6(18):2227-31. PubMed ID: 17671436
[TBL] [Abstract][Full Text] [Related]
13. Development of a First-in-Class Small-Molecule Inhibitor of the C-Terminal Hsp90 Dimerization.
Bhatia S; Spanier L; Bickel D; Dienstbier N; Woloschin V; Vogt M; Pols H; Lungerich B; Reiners J; Aghaallaei N; Diedrich D; Frieg B; Schliehe-Diecks J; Bopp B; Lang F; Gopalswamy M; Loschwitz J; Bajohgli B; Skokowa J; Borkhardt A; Hauer J; Hansen FK; Smits SHJ; Jose J; Gohlke H; Kurz T
ACS Cent Sci; 2022 May; 8(5):636-655. PubMed ID: 35647282
[TBL] [Abstract][Full Text] [Related]
14. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.
Guo A; Lu P; Lee J; Zhen C; Chiosis G; Wang YL
Oncogene; 2017 Jun; 36(24):3441-3449. PubMed ID: 28114285
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
[TBL] [Abstract][Full Text] [Related]
16. Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.
London CA; Acquaviva J; Smith DL; Sequeira M; Ogawa LS; Gardner HL; Bernabe LF; Bear MD; Bechtel SA; Proia DA
Clin Cancer Res; 2018 Dec; 24(24):6396-6407. PubMed ID: 30171047
[TBL] [Abstract][Full Text] [Related]
17. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors.
Rodrigues Moita AJ; Bandolik JJ; Hansen FK; Kurz T; Hamacher A; Kassack MU
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167494
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
19. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
20. Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression.
Zou M; Bhatia A; Dong H; Jayaprakash P; Guo J; Sahu D; Hou Y; Tsen F; Tong C; O'Brien K; Situ AJ; Schmidt T; Chen M; Ying Q; Ulmer TS; Woodley DT; Li W
Oncogene; 2017 Apr; 36(15):2160-2171. PubMed ID: 27721406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
